back to company universe
AI infrastructure

NeuroX1

Computational drug discovery leveraging generative AI to create therapeutics for neurodegenerative disorders.

sources
1
Evidence entries preserved.
affiliations
1
Techstars
competitors
6
Mapped from High Signal graph features.
status
generated
D1 lookup
last updated
2026-07-15
16:41 UTC
source evidence
Why this company exists here

Techstars

techstars-portfolio #2184

Computational drug discovery leveraging generative AI to create therapeutics for neurodegenerative disorders.

source
generated read
High Signal interpretation

NeuroX1 is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.

offline extraction
Product facets
generative AIneurodegenerative disordersComputational drug discoverytherapeutics
mapping method
Similarity graph

Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.

discovery cluster

Companies similar to NeuroX1

AI infrastructure · 6 peers

A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.

Harmonic Discovery

match 67

We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing

shared extracted concept terms: computational, drug, discovery; shared product terms: drug, discovery, therapeutic, computational; shared product theme: health and clinical care

Nanograb

match 65

Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.

shared extracted concept terms: computational, drug, discovery; shared product terms: computational, drug, discovery, create; same category: AI infrastructure

Sixfold Bioscience

match 41

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

shared extracted concept terms: drug, therapeutic; shared product terms: drug, therapeutic; shared product theme: health and clinical care

Ecomtent

match 40

Azoma is helping the world's leading brands, such as Mars, Colgate, HP, Beiersdorf, Zappos, P&G, and Reckitt, stay dominant in the era of AI Discovery with their end-to-end, enterprise, Generative Engine Optimization solution.

shared extracted concept terms: discovery, generative; shared product terms: discovery, generative; same category: AI infrastructure; shared affiliation: Techstars

Sequence Bio

match 36

90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.

shared extracted concept terms: drug, discovery; shared product terms: drug, discovery

Exin Therapeutics

match 36

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-N

shared extracted concepts: therapeutics; shared product terms: therapeutic, disorder; shared product theme: health and clinical care; same category: AI infrastructure